BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li H, Zhu J, Xu YW, Mou FF, Shan XL, Wang QL, Liu BN, Ning K, Liu JJ, Wang YC, Mi JX, Wei X, Shao SJ, Cui GH, Lu R, Guo HD. Notoginsenoside R1-loaded mesoporous silica nanoparticles targeting the site of injury through inflammatory cells improves heart repair after myocardial infarction. Redox Biol 2022;54:102384. [PMID: 35777198 DOI: 10.1016/j.redox.2022.102384] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Shao R, Li W, Chen R, Li K, Cao Y, Chen G, Jiang L. Exploring the molecular mechanism of notoginsenoside R1 in sepsis-induced cardiomyopathy based on network pharmacology and experiments validation. Front Pharmacol 2023;14:1101240. [PMID: 36713827 DOI: 10.3389/fphar.2023.1101240] [Reference Citation Analysis]
2 Liu M, Ramponi C, Fan X, Zhang X, Cao L, Wang Z, Xiao W. Nanoparticle-based Drug Delivery System for Post Myocardial Infarction Management. IJDDP 2022. [DOI: 10.53941/ijddp.v1i1.171] [Reference Citation Analysis]
3 Florensa M, Llenas M, Medina-Gutiérrez E, Sandoval S, Tobías-Rossell G. Key Parameters for the Rational Design, Synthesis, and Functionalization of Biocompatible Mesoporous Silica Nanoparticles. Pharmaceutics 2022;14. [PMID: 36559195 DOI: 10.3390/pharmaceutics14122703] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Wang Y, Xue Y, Guo H. Intervention effects of traditional Chinese medicine on stem cell therapy of myocardial infarction. Front Pharmacol 2022;13:1013740. [DOI: 10.3389/fphar.2022.1013740] [Reference Citation Analysis]